Syndax Pharmaceuticals (SNDX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SNDX Syndax Pharmaceuticals

Watchlist

15.815
-0.135-0.85%

Trading Nov 21 13:41 ET

1.35BMarket Cap-4344P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Analysts Supportive of Kura/Kirin Deal Despite Major Selloff in Shares
Seeking Alpha12:14 ET
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $38
Moomoo NewsNov 21 06:31 ET · Ratings
Syndax Pharmaceuticals Is Maintained at Buy by Citigroup
Dow JonesNov 19 12:03 ET · Ratings
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Seeking AlphaNov 19 11:06 ET
Scotiabank Maintains Syndax Pharmaceuticals(SNDX.US) With Hold Rating, Maintains Target Price $18
Moomoo NewsNov 19 08:31 ET · Ratings
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $33 to $51
Moomoo NewsNov 19 08:00 ET · Ratings

Comments

J.P. Morgan analyst has maintained their bullish stance on stock, giving a Buy rating on November 13. Goldman Sachs give it price target $31.

$Syndax Pharmaceuticals (SNDX.US)$

2

My watchlist Monday. Why? FDA approval- first of its kind for acute adult and pediatric leukemia

$Syndax Pharmaceuticals (SNDX.US)$

2

Repost of FDA approval! Longer PR because to me this seems like a pretty big deal? More so than most approvals! JMO

$Syndax Pharmaceuticals (SNDX.US)$ But im sure/hoping Dr @Jaguar8 will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...

2

6

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

3

2

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· just
FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation

2

2

Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

US

Overall

No Data